Octave provides precision care solutions for multiple sclerosis (MS) and other conditions. The company focuses on using data to generate insights for healthcare.

Octave

Gesund.ai empowers medical AI developers to establish, optimize, and sustain their AI lifecycles, ensuring privacy, compliance, speed, and scalability.

Gesund.ai

Octave® Bioscience Inc. is a commercial stage precision-medicine company delivering a new paradigm of care for Multiple Sclerosis and other neurodegenerative diseases. Octave’s Precision Care Solution is the industry’s first set of measurement tools that accurately and objectively measure disease activity, progression, and severity, allowing for better management of complex and high-cost neurodegenerative diseases, starting with Multiple Sclerosis and expanding into Parkinson’s disease. The Octave Solution includes the Octave MSDA Test, the first and only multivariate blood test for Multiple Sclerosis, that measures disease activity, enhanced MRI analytics and protocols, and a clinical care program that tracks and connects patients with MS certified nurse care partners in real time. By combining and analyzing multiple biological and contextual layers of data, delivering longitudinal and holistic perspectives of each patient, and revealing insights at population levels, the Octave Solution addresses unmet needs across the entire ecosystem of care, from patients and providers to pharma and payers. Octave  is currently collaborating with leading clinics, payers, and pharma companies across the country.


Michael J. Fox Foundation

Echo Health Ventures

Section 32 BlueCross BlueShield Venture Partners

Northpond Ventures

Deerfield

Casdin Capital

The Blue Venture Fund

Merck Global Health Innovation Fund

Hikma Ventures

Intermountain Ventures

🚀 Exciting News! 🚀

We are thrilled to share that Octave has been invited to participate in the Multiple Sclerosis and Neuroimmune Summit 2.0 hosted by Dr. Terry Wahls MD and presented by DrTalks.com 🥼

📅 Dates: August 20th - August 26th

We are incredibly honored to be part of this influential event and look forward to connecting with industry leaders and innovators. Catch our presentation titled "Track MS Progress: Key Biomarkers Explained"—a deep dive into how Octave’s Multiple Sclerosis Disease Activity (MSDA) Test is used in establishing a baseline and improving longitudinal clinical management in MS care.

💡Claim your free spot to join the Summit to learn from 40+ world-leading experts: https://lnkd.in/gkyDhvwa 

#DrTalks #Innovation #Biomarkers #Octave #PrecisionMedicine

We are thrilled to announce the newest addition to our leadership team at Octave — please join us in welcoming Marcel Konrad, CPA as our new Chief Financial Officer!

With a distinguished career in financial strategy and corporate leadership, Marcel brings a wealth of experience and a proven track record of driving financial excellence and strategic growth. 

In his new role at Octave, Marcel will lead our financial strategy, enhance our operational efficiency, and drive our commitment to delivering exceptional value to our stakeholders. We are confident that his expertise and vision will be instrumental in shaping our growth and allow us to continue delivering our #PrecisionCareSolution to more patients. 

Read more here: https://lnkd.in/gY-FySyH

#Welcome #Octave #Neurodegenerativedisease

Thank you Ferhan Qureshi for representing Octave at the #Olinkbiomarkersummit and presenting "The Octave MSDA test product journey: Improving insights for patients with MS utilizing a clinically validated assay developed on the Olink Proteomics platform."
#Olink #biomarker #precisionmedicine

Go check out Stephen Krieger and Kelly Leyden at American Academy of Neurology Wednesday 4/17 @ the 5:30 pm - 6:30 pm poster session. One of the coolest projects I’ve ever been a part of…bringing the topographical model into the 3D brain space. You will NOT be disappointed. #brain #3D #multiplesclerosis #medicaleducation #scicomm 🧠🧪 Octave 

https://lnkd.in/eTpWmzYC

A peek at some of the Americas Committee for Treatment & Research in Multiple Sclerosis (ACTRIMS) posters we'll be sharing tonight from 6-7:30.  https://lnkd.in/eNEt66Ad for all titles. 
#multiplesclerosis #precisioncare

Thank you Critical Path Institute (C-Path), we look forward to our partnership.

Metric
Company Name	Octave	Gesund.ai
Symbol
MSH ID	COM:OCTAVEBIO	AI:GESUND
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Healthcare Technology	Healthcare Technology
Country	US	DE
Stage
Employee Count	86
Website	octavebio.com	gesund.ai
LinkedIn	octave-bio	gesund-ai
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	65.47K	176
Web Traffic Growth	0.10	-0.50
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:OCTAVEBIO

Octave

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue